Home / Pharmaceuticals / Human Chorionic Gonadotropin Market By Treatment (Female Infertility Treatment, Oligospermia Treatment, Cryptorchidism Treatment), By Technology (Natural Source Extraction, Recombinant Dna Technology) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Human Chorionic Gonadotropin Market By Treatment (Female Infertility Treatment, Oligospermia Treatment, Cryptorchidism Treatment), By Technology (Natural Source Extraction, Recombinant Dna Technology) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: Jul 2016 | Report Code: 57982-07-16

Fertility patterns worldwide have changed dramatically and a rise in the infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.

This report studies the global human chorionic gonadotropin (HCG) market based on use of human chorionic gonadotropin in various treatments and production technologies. HCG is widely used for female infertility treatment, oligospermia, and cryptorchidism treatments. Based on manufacturing technologies the HCG market is categorized into natural source extraction and recombinant DNA technology. This report studies these segments in terms of their historical and future market size and forecast for the period 2014-2022. Respective compounded annual growth rates (CAGR %) for these segments for the period 2016-2022 are also presented in this study.

Geographically, the global human chorionic gonadotropin market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Middle East and Africa
  • Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 are also provided in this report.

Qualitative information such as drivers, restraints and future opportunities for the global hospital acquired disease testing market are included in this report. Competition assessment tools such as competition analysis and attractive investment proposition are presented in this study for scrutinizing competition of the global human chorionic gonadotropin market. This study concludes with company profiles section that highlights information about the key companies engaged in development, manufacture and provision of human chorionic gonadotropin products.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Human Chorionic Gonadotropin Market, by Therapeutic Area, 2015 (USD Mn)
2.2 Global Human Chorionic Gonadotropin Market, by Technology, 2015 (USD Mn)
2.3 Global Human Chorionic Gonadotropin Market, by Therapeutic Area Market, by Geography, 2015 (Value %)

Chapter 3 Global Hematopoietic Stem Cells Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 High Infertility Prevalence Worldwide
3.3 Market Restraints
3.3.1 Availability of Substitutes
3.4 Market Opportunities
3.4.1 Demand for Recombinant HCG
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Human Chorionic Gonadotropin Market, by Key Players

Chapter 4 Global Human Chorionic Gonadotropin Market Analysis, By Treatment
4.1 Overview
4.2 Female Infertility Treatment
4.3 Oligospermia Treatment
4.4 Cryptorchidism Treatment
4.5 Others

Chapter 5 Global Human Chorionic Gonadotropin Market Analysis, By Technology
5.1 Overview
5.2 Natural Source Extraction
5.3 Recombinant DNA Technology

Chapter 6 Global Human Chorionic Gonadotropin Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Ferring B.V.
7.1.1 Ferring B.V.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.2 Bristol Mayer Squibb Company
7.2.1 Bristol Mayer Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.3 EMD Serono, Inc.
7.3.1 EMD Serono, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.4 Fresenius Kabi USA, LLC
7.4.1 Fresenius Kabi USA, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.5 Merck & Co., Inc.
7.5.1 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Table :

TABLE 1 Therapeutics Category
TABLE 2 Market Competition Assessment: Human Chorionic Gonadotropin Products, by Key Players
TABLE 3 Global Human Chorionic Gonadotropin Market, by Treatment, 2014-2022 (USD Mn)
TABLE 4 Global Human Chorionic Gonadotropin Market, by Technology, 2014-2022 (USD Mn)
TABLE 5 Global Human Chorionic Gonadotropin Market, by Geography, 2016 – 2022 (USD Mn)
TABLE 6 Ferring B.V.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Bristol Mayer Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 EMD Serono, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Fresenius Kabi USA, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Figure :

FIG. 1 Human Chorionic Gonadotropin Market: Research Methodology
FIG. 2 Global Human Chorionic Gonadotropin Market, by Therapeutic Area, 2015 (USD Mn)
FIG. 3 Global Human Chorionic Gonadotropin Market, by Technology, 2015 v/s 2022 (Value %)
FIG. 4 Global Human Chorionic Gonadotropin Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2015
FIG. 6 HCG Market in Female Infertility Treatment, 2014 – 2022 (USD Mn)
FIG. 7 HCG Market in Oligospermia Treatment, 2014 – 2022 (USD Mn)
FIG. 8 HCG Market in Cryptorchidism Treatment, 2014 – 2022 (USD Mn)
FIG. 9 HCG Market in Other Treatments, 2014 – 2022 (USD Mn)
FIG. 10 HCG from Natural Source Extraction Market, 2014 – 2022 (USD Mn)
FIG. 11 HCG from Recombinant DNA Technology Market, 2014 – 2022 (USD Mn)
FIG. 12 North America Human Chorionic Gonadotropin Market, By Country, 2013 – 2022 (USD Mn)
FIG. 13 Europe Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (USD Mn)
FIG. 14 Asia-Pacific Human Chorionic Gonadotropin Market , 2013 – 2022 (USD Mn)
FIG. 15 Latin America Human Chorionic Gonadotropin Market, 2016 – 2022 (USD Mn)
FIG. 16 Middle East and Africa Human Chorionic Gonadotropin Market, 2016 – 2022 (USD Mn)

Based on therapeutic areas, the global human chorionic gonadotropin market categorized into:

  1. Female Infertility Treatment
  2. Oligospermia Treatment
  3. Cryptorchidism Treatment
  4. Others

Human Chorionic Gonadotropin Market

Infertility treatment in both males and females is the major treatment area where HCG is commonly administered. Growing incidence of infertility in women, contributed by increased maternity age, lifestyle effects and others, hormonal dysfunctions in men and growing incidence of oligospermia are the key factors that have supported the demand for HCG drugs in the market. The demand for HCG is steady in developed markets of Europe and North America. On the other hand, growing awareness in general population and development of healthcare infrastructure are supporting the growth in demand for HCG drugs in emerging markets. Female infertility, oligospermia and cryptorchidism are the key conditions for which HCG drugs are indicated.Among the various uses of HCG, the consumption of the drug is the highest in female infertility treatment. HCG is used to cause ovulation and for treating infertility. However, Category X rating to the drug by the US FDA, risk of multiple pregnancies, and risk of developing life threatening ovarian hyperstimulation syndrome (OHSS) are some of the factors that hold back the demand for HCG drugs in the market.

Based on manufacturing technology, global human chorionic gonadotropin market categorized into:

  1. Natural Source Extraction
  2. Recombinant DNA Technology

Human Chorionic Gonadotropin Market

Urine-derived HCG has been a chief treatment source for various hormonal conditions. However, in view of purity related issues, HCG manufacturing through recombinant production technology. Equal efficacy or recombinant HCG along with added safety as against natural source HCG are the key driving factors that lead to higher demand for recombinant HCG in the global market.Recombinant HCG is derived from ovary of genetically engineered Chinese hamster through recombinant DNA technology. Repeated chromatographic steps are sued for purification of the product to deliver highly specific activity outcome, this making the drug free form urinary contaminations, thus suitable for injection and self-administration in ART, delivering higher tolerability and reduced local reactions.

Based on geographical segmentation, the human chorionic gonadotropin market is studied for:

  • North America
    • US
    • Canada 
  • Europe
    • UK
    • Germany
    • Fance
    • Rest of Europe
  • Asia-Pacific
    • Japa
    • China
    • India
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa

Human Chorionic Gonadotropin Market

North America is expected to be the largest and most potential regional market forhuman chorionic gonadotropin. North America constitutes regional markets of U.S.and Canada, the rising incidence of infertility cases, lifestyle effects and others,hormonal dysfunctions in men and women are the major driver for the growth ofthe global human chorionic gonadotropin market. Asia-Pacific is the expected to bethe most potential regional market for human chorionic gonadotropin market by2022. Over the next six years, the growth of the market in the Asia-Pacific region islikely to be centered in Japan, South Korea, China, and India. Numerous factorssuch as developing economical landscape, increasing disposable incomes, growingpublic awareness related to infertility therapy, and increasing government supportthrough providing favorable policies are the major factors expected to assist thegrowth of Asia-Pacific market.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients